Tedeschi, Alessandra
 Distribuzione geografica
Continente #
EU - Europa 358
NA - Nord America 321
AS - Asia 156
OC - Oceania 6
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 843
Nazione #
US - Stati Uniti d'America 317
IT - Italia 168
SE - Svezia 102
SG - Singapore 78
CN - Cina 48
IE - Irlanda 35
ID - Indonesia 21
DE - Germania 14
RU - Federazione Russa 10
GB - Regno Unito 6
FI - Finlandia 5
IN - India 5
AU - Australia 4
CA - Canada 4
ES - Italia 4
FR - Francia 3
GR - Grecia 2
IL - Israele 2
NZ - Nuova Zelanda 2
PL - Polonia 2
UA - Ucraina 2
BE - Belgio 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EU - Europa 1
JP - Giappone 1
LT - Lituania 1
NG - Nigeria 1
NL - Olanda 1
TR - Turchia 1
Totale 843
Città #
Florence 80
Singapore 67
Chandler 57
New York 45
Ashburn 42
Dublin 33
Milan 22
Jakarta 21
Beijing 18
Chicago 11
Princeton 10
San Mateo 8
Wilmington 8
Moscow 7
Rome 7
Washington 7
Dearborn 6
Los Angeles 6
Norwalk 5
Acerra 4
Benalla 4
Boston 4
Pellezzano 4
Pune 4
Asti 3
Brescia 3
Helsinki 3
Redmond 3
Sesto Fiorentino 3
Bagheria 2
Berzo Inferiore 2
Bremen 2
Bruino 2
Cattolica 2
Fairfield 2
Garden City 2
Gdansk 2
Houston 2
Kunming 2
Lappeenranta 2
London 2
Marcianise 2
Monteriggioni 2
Nanjing 2
Ottawa 2
Pottstown 2
Tarragona 2
Verona 2
Whangarei 2
Acton 1
Atlanta 1
Berlin 1
Brno 1
Brussels 1
Casoria 1
Chennai 1
Cuceglio 1
Dello 1
Denver 1
Forest City 1
Hamburg 1
Hebei 1
Hefei 1
Izmir 1
Jinan 1
Lagos 1
Marseille 1
Nanchang 1
Naritahigashi 1
Ningbo 1
Nuremberg 1
Pavia 1
Ponte San Pietro 1
Redwood City 1
San Giovanni Teatino 1
Santa Rosa 1
Sarno 1
Seattle 1
Shenyang 1
Suzhou 1
Toronto 1
Trieste 1
Vancouver 1
Vergiate 1
Vigliano Biellese 1
Xian 1
Zurich 1
Totale 573
Nome #
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 68
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 63
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 62
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion 58
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 58
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 51
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 46
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 46
Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib? 45
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 44
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 44
Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes 41
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 34
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 31
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 28
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 28
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 27
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort 26
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 26
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 23
I complessi sacri e i culti di Praeneste tra l'età arcaica e l'età tardo repubblicana 10
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody? 7
Totale 866
Categoria #
all - tutte 5.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.303


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202034 0 0 0 0 2 3 6 4 16 1 2 0
2020/202117 0 3 0 1 1 2 0 0 1 6 2 1
2021/2022111 2 0 17 18 12 3 4 10 6 5 27 7
2022/2023215 34 26 16 12 15 23 4 13 28 8 32 4
2023/2024356 16 58 37 59 20 83 17 4 1 8 13 40
2024/2025110 8 4 39 8 51 0 0 0 0 0 0 0
Totale 866